ArticleLeukemia2024

In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.

Ho-Jae Han et al.PubMed ↗Publisher ↗

No numbers read from the abstract.